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The Ethics of Subject Selection for Testing
Live-Attenuated HIV Vaccines
JERMMY GRUSHCOWt
Over 30 million people worldwide are infected with Human Immunodefi-
dency Virus (HIV), the virus that causes AIDS.' More than 2 million people
died of AIDS in 1997 alone, including 39,200 in the U.S. The best long term
solution to the HIV pandemic is the development of an effective vaccine. How-
ever, vaccine testing must be performed on uninfected subjects, exposing them
to uncertain risk and certain adverse social consequences.2 Three subject popula-
tions have been proposed for vaccine trials: doctors and health-care workers;3
terminally ill cancer patients 4 and citizens of developing countries5 This paper
considers the ethical merits of using each of these populations at different stages
of vaccine testing and concludes that doctors are the most appropriate popula-
tion for early stages of testing, that populations in developing countries are the
t. Jeremy Grushcow is a Ph.D. candidate in Molecular Genetics and Cell Biology at the
University of Chicago. He received his B.S. from the University of Toronto in 1995. The author
would like to thank Jessica Berg for her many helpful comments, while noting that all errors are
his alone.
1. UNAIDS and WHO, Report on the Global HIV/AIDS Epidemic, Figure 3 (Dec 1997) at
<http://www.us.unaids.org/highband/document/epidemic/report97.html>.
2. One of the main quandaries posed by HIV vaccine testing is that test subjects will test
positive in some or all tests for the virus, and may be subject to discrimination as if they were
HIV positive. Chris Collins, Sustaining Suiport for Domestic HWV Vaccine Research: Social Issues Over
the Long Haul of Human Trials, CAPS-Center for AIDS Prevention Studies, Occasional Paper
#2 (July 1996) at <http://hivinsite.ucsfedu/topics/vaccines/2098.2914.html>.
3. Jon Ungoed-Thomas, Doctor to Test HIT Vacdne on Himself, Sunday Times-London (Mar
1, 1998), 1998 WL 8043043; Deborah L. Shelton Leading by Exaple: Doctors Offer Themselves as
Candidates to Spur HIV Vaccine Trial, 41 Am Med News (Jan 12, 1998) at <http://www.ama-
assn.org/special/hiv/newsline/special/amnews/011298.htm>.
4. Proposed Live HIV Vacdne Trials Face Many Problems, 12/1/97 AVAB, 1997 WL 9577778;
Shelton, 41 Am Med News (Jan 12, 1998) (cited in note 3).
5. Lilliane Barenzi and Charles Wendo, AIDS Vaccine Trials to Start, Africa News Service
(Mar 5, 1998), 1998 WL 10884235; Barry R. Bloom, The Highest Attainable Standard: Ethical Issues
in AIDS Vaccines, 279 Science 186 (an 9, 1998).
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most appropriate for later stages, and that terminal cancer patients are wholly
inappropriate subjects.
I. AN HIV VACCINE
A. THE NEED FOR A LiVE-ATYENUATED HIV VACCINE
As one physician has observed, "[i]f we're really going to kick [HIV] in the
butt it's going to have to be with a vaccine." 6 Despite the publicity generated by
effective drug treatments in developed countries,7 a vaccine is superior to drugs.
Because antiviral drugs do not fully eradicate HIV infection, but only keep it in
check, they require that patients have long-term access to medical care. Unlike
antibiotics, which can clear bacterial infections over a short course of treatment,
antiviral drugs must be taken continually to prevent a resurgence of the viral
infection. Because antiviral drugs must be taken long term, the costs of treatment
mount quickly. Furthermore, long-term patient commitment is necessary. In
contrast, vaccination often requires only one encounter with health care workers,
so the benefits can be realized without a lifetime of medical treatment. Because
the vast majority of HIV infected people worldwide will never be able to afford
antiviral drug treatment8 and do not have access to the life long care such treat-
ment requires, the development of an HIV vaccine is essential to bringing the
global spread of AIDS under control.
Vaccines work by introducing the immune system to a virus in a modified
form that cannot cause disease. This allows the body to learn to recognize the
virus and respond effectively to it in the future.9 Three kinds of modified viruses
have been used for vaccination: subunit vaccines, killed vaccines, and live-
attenuated vaccines. Neither subunit vaccines nor killed vaccines are likely to be
appropriate for clinical use. Subunit vaccines are the safest option because they
introduce only a small, impotent portion of the virus. However, a subunit vac-
cine against HIV is not likely to be effective because HIV is much more variable
than most viruses. Consequently, there are now five major and several more
minor subtypes of HIV in the world, each of which differs by about 30 percent
6. Shelton, 41 Am Med News, (quoting Dr. Andrew M. Pavlatos) (cited in note 3).
7. The CDC's latest published statistics show the first recorded decrease in the number of
AIDS deaths in the U.S. CDC, 9 HIV/AIDS Surveillance Report 3 (mid-year ed 1997). However,
the number of people infected with HIV continues to rise, with almost 65,000 new cases re-
ported in the U.S. between June 1996 and June 1997. Id at 5.
8. "For example, Uganda ... [has] ... an annual per capita expenditure on health of $6 ...
[compared to] ... the $12,000 to $15,000 annual cost for antiretroviral therapy." Bloom, 279
Science at 187 (cited in note 5).
9. The immune system protects against future infection in two ways. First, it produces
antibodies, which are molecules that bind to and neutralize a virus ("humoral immunity"). Sec-
ond, the immune system maintains a small reserve of cells that remember the virus and can be
multiplied and remobilized to fight a new infection with the virus ("cellular immunity"). It is
unclear whether an HIV vaccine will need to induce either a cellular or humoral response, or
both, in order to ensure that subsequent exposure to HIV will not result in an infection.
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from the others.10 A subunit vaccine developed to fight against one subtype will
not necessarily protect against other subtypes. Furthermore, a subunit vaccine
developed against one subtype may not even protect against that same subtype
months later due to the rapid mutation rate of the virus. Empirical data so far
have supported the prediction that subunit vaccines will not work." Killed vac-
cines are the next safest alternative. However, the technology does not currently
exist to produce a killed HIV vaccine.12 Given the problems associated with sub-
unit and killed vaccines, a successful HJV vaccine will most likely take the form
of a live-attenuated virus.
Live-attenuated vaccines are potentially the most dangerous but have histori-
cally been the most effective. The global eradication of Smallpox, and the victo-
ries against Rabies, Polio, Measles, Mumps, German Measles, Chickenpox and
Shingles, among others, are testaments to the effectiveness of live-attenuated
viruses for vaccination. 13 So far, studies using animal models of HIV suggest that
live-attenuated vaccines may be the best hope in this case as well.14 However,
10. Mark Bowers, HI'V Vacdnes, (San Francisco AIDS Foundation, 1996) at <http:// hivin-
site.ucsf.edu/topics/vaccines/2098.2158.html>.
11. "[Vaccination with recombinant =Y immunogens induces high levels of antibodies but
... these do not bind to or neutralize the field virus." Safe, Effective AIDS Vacdne Highly Unlikey
Within Ten Years, Reuters Health Information (Feb 2, 1998), reporting on Dr. David Baltimore's
keynote address to the 5th Conference on Retroviruses and Opportunistic Infections, at
<http://www.ama-assn.org/special/hiv/newsine/conferen/retro98/020298a1.htm>. Fur-
thermore, a summary of data from phase I and phase II trials found that nineteen vaccinated
subjects nevertheless acquired HIV-1 infection, compared to four HIV infections among sub-
jects who received a placebo. B.S. Graham, et. al., Anaylsis of Intercurrent Human Immuodeidengy
Virs Tyfie 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines, 177 J Infect Diseases 310
(Feb 1998); "[We conclude that vaccination with rgpl20 has had, to date, no obvious beneficial
or adverse effects on the individuals we have studied." RI. Connor, et al, Immunological and Vi-
rologicalAnalyses of Persons Infected ly Human Immunodefcieny Virus Tlbe 1 While Particpating in Trials
of Recombinant &120 Subunit Vacdnes, 72 J Virol 1552 (1998). AIDS Vacdne Evaluation Study Group
Results Presented In Vancouver, Reuters Health Information (July 8, 1996) at <http://www.ama-
assn.org/special/hiv/newsline/conferen/aidsll/708artl2.htm>. More recent early stage clinical
trials that use more highly immunogenic presentations of HIV subunits are ongoing. These may
show more promise than earlier subunit vaccines.
12. Killed virus does not stimulate the immune system to nearly as great an extent as live
virus. Therefore, in order to induce protective immunity with a killed vaccine, enormous quanti-
ties of virus are required. The cultivation of such quantities of HIV is beyond the ability of
current technology.
13. Susan L Plotkin, M.S.L.S., and Stanley A. Plotkin, M.D., A Short Histoy of Vacdnation, in
Stanley A. Plotkin, M.D. and Edward A. Mortimer, Jr., M.D. eds, Vaccines 1, 5 (W.B. Saunders
Company 2d ed 1994).
14. "To date, vaccine approaches based on live attenuated SIV [simian immunodeficiency
virus] have exhibited the greatest degree of efficacy and provide opportunities for defining
correlates of immune protection." NIH Office of Aids Research (OAR), General Information,
IlV/AIDS-Related Research Program: Vacdnes, (last update Feb 17, 1998), at
<http://www.nih.gov/od/oar/OARVACC.HTM>; "Historically and statistically, the vaccines
with the best chance of succeeding are live-attenuated vaccines, which use weakened forms of
the actual virus. Of the vaccines tested thus far, live-attenuated vaccines have provided the most
consistent and broadest protection in SIV-infected monkeys." Deborah L. Shelton AIDS Vac-
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live-attenuated vaccines for HIV are ethically problematic because they risk giv-
ing subjects AIDS, which is incurable. A live-attenuated vaccine for HIV also
poses a second problem. HIV is a retrovirus, which means that one of its first
acts upon infecting a cell is to insert itself into the host cell's DNA where a copy
resides permanently. This permanence means that even a successful attenuated
vaccine would cause a life-long latent infection with weakened HIV.15 This is
dangerous for two reasons. First, there is a theoretical possibility that ongoing
low level viral replication could contribute to the development of cancer in vac-
cinated individuals. Second, it is theoretically possible that the integrated viral
genome from the vaccine could recombine with virus from a later (accidental)
exposure to reconstitute a potent infectious variety. Because both the risks and
the benefits of a live-attenuated vaccine are great, such vaccines pose a signifi-
cant ethical challenge to those responsible for evaluating the safety and efficacy
of HIV vaccines.
B. DEVELOPING AN HIV VACCINE
In the U.S., monitoring the clinical trials of vaccines is the responsibility of the
Center for Biologics Evaluation and Research (CBER) of the Food and Drug
Administration (FDA). This authority was vested in the CBER and its predeces-
sors in response to a dizzying history of abuse of research subjects.16 In submit-
ting an application for clinical testing of an "Investigational New Drug (IND),"17
dne: Rhetoric or Realio? Am Med News (Aug 18, 1997), at <http://www.ama-
assn.org/special/hiv/newsline/special/amnews/amnO8l8.htm>.
15. Dennis Panicali, Ph.D., President and CEO of Therion Biologics Corp. (the company
that plans to submit a proposal for a live-attenuated vaccine to the FDA) admits: "This will be a
chronic viral infection and [trial subjects] have to expect to live with this virus for the rest of
their lives." Shelton, 41 Am Med News (cited in note 3).
16. In 1901, thirteen children died in the United States from live tetanus which contaminated
a batch of diphtheria antitoxin. Paul D. Parkman, M.D., and M. Carolyn Hardegree, M.D.,
"Regulation and Testing of Vaccines," in Plotkin and Mortimer, eds. Vaccines 889, 891 (cited in
note 13), citing R.A. Kondratas, Death Helped Write the Biologics Law, 16 FDA Consumer 23-25
(1982). That tragedy resulted in the first legislative regulation of medicines, the Biologics Con-
trol Act or Virus, Serum, Toxin Law, which was enacted July 1, 1902. Carol Grady, R.N., Ph.D.,
The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive HIV Vac-
dme, 33 (Indiana 1995); The deaths of more than one hundred people from a substance called
"Elixir Sulfonamide" in 1937 led to the passage of the Food, Drug and Cosmetic Act, which
mandated testing for safety. Id at 34; The birth defects caused by Thalidomide prompted the
Kefauver-Harris amendments in 1962, which required a demonstration of efficacy as well as
safety. Id at 38. In 1972, the public discovered the government run Tuskegee experiment, in
which poor black men in rural Alabama who had contracted syphilis were observed but not
treated so that researchers could gather data about the natural course of the disease. Rebecca
Dresser, Draft Materials for Bioethics and Law, 15 (West, forthcoming) citingJ. Jones, Bad Blood" The
Tuskegee Sphilis Experiment, (rev ed 1993) and Twenty Years After The Legafy of the Tuskegee Syphiis
Study, Hastings Center Rep. 29 (Nov-Dec 1992). Revelations about Tuskegee led to the passage
of the National Research Act in 1974. Grady, The Searchfor an AIDS Vaccine at 41.
17. Parkman and Hardegree, Regulation and Testing of Vaccines, in Plotkin and Mortimer, Vac-
cines, 889, 894 (cited in note 13).
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the sponsor must describe the safety of the manufacturing process, the labora-
tory (m vitro) and animal Cin vivo) testing data, and the qualifications of the in-
vestigators.18 The FDA mandates three phases of clinical trials to demonstrate
both the safety and the efficacy of an IN-D before it will approve the IND for
commercial distribution.19
Phase I and phase II clinical trials are primarily meant to evaluate safety. Phase
I trials enroll a small number of (often healthy) subjects to test for safety and, in
the case of vaccines, to test for indications that an immune response is being
generate&O2 Phase I trials expand on phase I data, optimize dosage regimens,
and may compare the immunogenicity of different vaccines.2' Preliminary indica-
tions of efficacy in phase II are compared with cumulative data on safety and
short-term side effects in order to decide whether to proceed to phase Ill. Phase
Ill trials enroll large numbers of subjects to determine the efficacy of the IND
and, in the case of vaccines, requires subjects who are at risk for the disease.
Phase I trials for vaccines require several thousand participants22
With close to 16,000 people being infected with HIV every day some have
argued that "[flailing to proceed [with HIV vaccine development and testing] is
unethical and violates basic human rights (emphasis added)."24 However, there is
a competing ethical obligation to protect research subjects (and the public) from
dangerous or ineffective products. In deciding whether and when to begin the
clinical trials required by the FDA, research sponsors must be guided by the
ethical framework set out in the Belmont Report.
II. THE BELMONT REPORT
The Belmont Report was prepared by the National Commission for the Pro-
tection of Human Subjects of Biomedical and Behavioral Research in 19793
The Commission was created by the National Research Act in 1974,6 and was
18. Id (citing 21 CFR 312 (1992)).
19. Id at 895.
20. The US Congress, Office of Technology Assessment (OTA), Adverse Reactions to HIV
Vadnes: Medical, Ethica, and LegalIssues, OTA-BP-H-163 at 39 (Washington DC: US Gov Print-
ing Office, Sept 1995).
21. Id.
22. The first planned phase III trial for an HIV vaccine is currently underway using 5,000
volunteers in the US and a further 2,500 in Thailand. Michael Balter, Impending AIDS Vaccine
Trial Opens Old Wounds, 279 Science 650, 650 (Jan 30, 1998).
23. UNAIDS and WHO Report on the Global HIV/AIDS Epidemic, text accompanying Figure
2 (cited in note 1).
24. Jonathan M. Mann, M.D., M.P.H., Paralsis in AIDS Vacdne Development Violates Ethical
Principles and Human Rights, Speech to the Presidential Advisory Council on HIV and AIDS
(PACHA), (Mar 15, 1998) at <http://hivinsite.ucsf.edu/topics/vaccines/2098.3940.html>.
25. National Commission for the Protection of Human Subjects of Biomedical and Behav-
ioral Research, Ethical Principles and Guideines for the Protection of Human Suects of Research (The
Belmont Rep ort) (US Gov Printing Office, 1979).
26. Grady, The Searchfor an AIDS Vacine at 41 (cited in note 16).
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charged with formulating the "basic ethical principles that should underlie the
conduct of research involving human subjects, and ... guidelines to assure that
such principles are followed."2 7
The Belmont Report identifies three principles: autonomy, beneficence and
justice. These principles were incorporated into the Department of Health and
Human Services' (DHHS) regulations in 1981. By 1991, the DHHS regulations
had become the basis for regulation of research on human subjects throughout
the federal government's intra- and extramural research programs28 The princi-
ple of respect for persons translated into the policy of informed consente9 and
into special protection for vulnerable populations;30 beneficence into risk/benefit
analysis;31 and justice into a policy of appropriate subject selection to ensure eq-
uitable distribution of the risks and benefits of research.3 2 The Belmont Report
principles are challenged in new ways by the AIDS pandemic, and by proposals
to test preventative HIV vaccines.
A. AUTONOMY
The principle of autonomy reached its ascendancy in 1947, in the Nuremberg
Code. This document, which comprised part of the judgment at the Nazi Doc-
tors' Trial,33 placed the principle of informed consent above all other considera-
tions. Whereas other provisions in the Code leave room for balancing priorities,
the consent provision is absolute: "[t]he voluntary consent of the human subject
is absolutely essential." 34 Likewise, the Belmont Report's concern for autonomy
is manifested in its requirement that a research subject give his "informed con-
sent" to participate in a clinical trial.35
The current standard of informed consent for a particular clinical trial depends
on two factors: the risk of the proposed experiment,36 and the capacity of the
proposed subject to freely and deliberately assume the risks of the trial. 7 Because
of the uncertain but large risk associated with live-attenuated vaccine trials, a
high level of autonomy must be demanded from all subject pools. A subject's
autonomy can be assessed by monitoring three elements: information, compre-
hension, and voluntariness. 38 The information must be provided "in language
27. The Belmont Report, cover letter (Sept 30, 1978) (cited in note 25).
28. Dresser, Draft Materialsfor Bioethics and Law at 21 (cited in note 16).
29. Federal Policy for the Protection of Human Subjects, 56 Fed Reg 28003, 28016
(§111(a)(4)-(5)) (1991).
30. 56 Fed Reg 28003, 28016 (§111(b)).
31. 56 Fed Reg 28003, 28016 (§111(a)(2)).
32. 56 Fed Reg 28003, 28015-16 (§§111(a)(1)(ii), 111(a)(3)).
33. Michael A. Grodin, Historical Origins of the Nuremberg Code, in George J. Annas and Michael
A. Grodin, eds, The Nazi Doctors and the Nuremberg Code, 121 (Oxford Univ Press 1992).
34. The Nuremberg Code, in Annas and Grodin, The Nazi Doctors, 2 (cited in note 33).
35. The Belmont Report at 10 (cited in note 25).
36. Id at 11.
37. 56 Fed Reg 28003, 28016 ) (§116) (cited in note 29).
38. The Belmont Report at 10 (cited in note 25).
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understandable to the subject,"3 9 and the subject must be given "sufficient op-
portunity to consider '40 the information. A subject gives voluntary consent when
he is "free of coercion or undue influence."41 Each population's capacity to make
autonomous decisions about whether to participate in an HIV vaccine trial must
be assessed separately.
The task of assuring subject autonomy for HIV vaccine trials may be more
onerous than for other types of research because of the complexity of the sub-
ject matter. A recent empirical study of the willingness of high risk subjects to
participate in phase IHl HIV vaccine trials identified several relevant issues.42
First, the study found that 37 percent of the men were initially certain of their
willingness to participate in vaccine trials; but that one year later, almost half of
them had changed their minds.43 This finding reveals the importance of allowing
subjects sufficient time to consider the information presented; and suggests that
the amount of time necessary to reach an autonomous decision may be consid-
erably longer than is typically allowed. Disturbingly, the study also found a corre-
lation between continued willingness to participate and lower levels of educa-
tion.44 Furthermore, anecdotal evidence suggests that information about risks
needs to be fully and carefully presented, even to highly educated subjects. For
example, one physician volunteering for phase I HIV vaccine trials admitted, 'I
have this kind of Hollywood fantasy that, as a result of this clinical trial, someone
is going to do something and have an 'Ah-hah!' moment that's going to make the
big difference."45 Similarly, a volunteer at the AIDS Vaccine Evaluation Unit at
the University of Washington explained his willingness to participate in HIV
vaccine trials as follows: "I thought about how polio vaccine was developed,
how those volunteers might have felt I thought this would be a landmark study
to be involved with."46 Anyone with knowledge of the polio vaccine's develop-
ment would feel only terror at the prospect of participating in a repetition of that
process. When large-scale trials of the first polio vaccines were undertaken in
1936, there was not adequate data on the safety or immunogenicity of the vac-
cines. Many of those inoculated developed paralysis, often in the inoculated
limb.47 A further 260 cases of polio were caused by unsafe manufacturing of the
vaccine at the Cutter plant in 1955.48 Of course, informed consent does not nec-
39. 56 Fed Reg 28003, 28016 (§116) (cited in note 29).
40. Id.
41. The Belmont Report at 14 (cited in note 25).
42. Bradford N. Bartholow, et al., Assessment of the Changing Willingness to Participate in Phase rIf
H Vacdne Trials Among Men who Have Sex with Men, 16 J Acquir Immune Defic Syndr Hum
Retrovirol 108 (1997).
43. Id at 112.
44. Id at 110, 113.
45. Shelton, 41 Am Med News (cited in note 3).
46. AIDS Vaccine Evaluation Unit (AVEU), University of Washington, In Their Own Words-
The Volunteers Speak (1996) at <http://weber.u.washington.edu/-vaccine/pages
/InTheir0wnWords.html>.
47. Frederick C. Robbins, M.D., Polio--Historical, in Plotkin and Mortimer, eds, Vacdnes 137,
137-8 (cited in note 13).
48. Id at 140.
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essarily include an understanding of the history of vaccination. However, vaccine
trials do present unique hazards which must be properly explained.49 Care must
be taken to avoid overestimating the capacity of potential subjects to appreciate
the consequences of participation.
B. BENEFICENCE
The second Belmont Report Principle, the principle of beneficence, is as old
as medicine. Physicians taking the Hippocratic oath must swear the following- "I
will follow that system of regimes which, according to my ability and judgment, I
consider for the benefit of my patients, and abstain from whatever is deleterious
and mischievous. 50 This oath has been called the "golden rule" of the medical
profession.5'
A literal interpretation of the Hippocratic oath became problematic with the
advent of vaccines. Jenner's experiments with the cowpox virus in 1798 caused
his subjects mild illness, and the occasional deaths following Pasteur's inocula-
tion of patients with live-attenuated rabies virus in 1885 were viewed as medical
murder.5 2 Nevertheless, the vaccines that resulted from these experiments pre-
vented countless deaths. A new concept of "public health" emerged sometime
between Jenner and Pasteur, which embodied Jeremy Bentham's relatively new
philosophy of utilitarianism. In a modem interpretation of the Hippocratic
maxim, the Belmont Report acknowledges that "even avoiding harm requires
learning what is harmful; and, in the process of obtaining this information, per-
sons may be exposed to risk of harm."5 3 The principle of beneficence now
means ensuring that "[r]isks to subjects are reasonable in relation to ... the im-
portance of the knowledge that may reasonably be expected to result." 4
While an HIV vaccine has enormous potential for societal benefit, the sub-
stantial risks to trial subjects "carry special weight"55 under the Belmont Report's
beneficence principle. Foremost among these risks is the likelihood that partici-
pants in live-attenuated HIV vaccine trials will test positive in most, if not all,
commercially available HIV tests. This presents a risk of social harm equal to
that of actually having HIV.5 6 This risk can be minimized by providing verifica-
tion of the subject's participation in the trial 7 and of their (hopefully) negative
HIV status. In the future, this risk may be eliminated by the widespread applica-
49. An excellent discussion of the specific information which should be provided in in-
formed consent documents in vaccine trials can be found in OTA, Adverse Reactions to HIV
Vaccines (cited in note 20).
50. Grodin, Historical/Origins of the Nuremberg Code, 121, 123 (cited in note 33).
51. Id.
52. Plotkin and Plotkin, A Short History of Vaccination, in Plotkin and Mortimer, eds, Vaccines,
1, 2-3 (cited in note 13).
53. The Belmont Report at 7 (cited in note 25).
54. 56 Fed Reg 28003, 28015-6 (§111(a)(2)) (cited in note 29).
55. The Belmont Report, at 16 (cited in note 25).
56. OTA, Adverse Reactions to HIV Vaccines at 52 (cited in note 20).
57. Id at 53.
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tion of testing methodologies that can reliably differentiate between vaccinated
and infected subjects.
A second risk to potential subjects is the difficulty of identifying a useful and
safe trial endpoint. In the case of an influenza vaccine, the endpoint is the clini-
cal manifestation of flu symptoms, and the subsequent determination of the
exact nature of the infectious agent Waiting for symptoms of AIDS to manifest
themselves is an ethically unacceptable method of monitoring the effectiveness
of an HIV vaccine. Current standards of care in the U.S. mandate aggressive
antiviral treatment at the first sign of HIV infection. Because subjects cannot
presently rely on commercially available methods of testing, the trial sponsor
must proactively test for super-infection by naturally occurring strains of HIV
throughout the patient's life.
Aside from these benefits and risks, which apply to all HIV vaccine trials, each
potential subject population will be subject to unique risks and benefits. There-
fore, a risk/benefit analysis must be applied to each population separately.
C. JUSTICE
The third principle identified by the Belmont Report, the principle of justice,
requires "that there be fair procedures and outcomes in the selection of research
subjects."58 In order to ensure that subjects are selected fairly, the selection proc-
ess "needs to be scrutinized in order to determine whether some classes ... are
being systematically selected simply because of their easy availability, their com-
promised position, or their manipulability, rather than for reasons directly related
to the problem being studied." 9 Vaccine research in particular has often been
conducted on impoverished populations in developing countries 0 Such in-
stances have caused concern that the development of anti-HIV therapies could
lead to the unjust "exploitation of those with the least access to health care."61
Regardless of the population that is ultimately selected, the sponsor of the trial
must provide any product that results from the research to the community which
58. The Belmont Report at 18 (cited in note 25).
59. Id at 9-10.
60. The first large-scale field trial of a typhoid vaccine took place in 1896 using four thou-
sand volunteers from the Indian army at a time when there remained great controversy over the
vaccine's use in Britain. Waldemar Haffkdne, faced with an outbreak of the plague in Bombay in
1897, produced a killed plague vaccine and inoculated himself and 8,000 other people. In 1968,
after its approval for use in Japan, but before it was licensed in the U.S., the Centers for Disease
Control conducted large-scale trials of a vaccine against Japanese encephalitis virus in Northern
Thailand. In 1977, small-scale trials of a typhoid vaccine were carried out on a volunteer group
in the U.S., followed by large-scale trials in Egypt in 1982, and in Chile in 1987. Plotkin and
Plotkin, A Short History of TVaceination, 1, 4-7 (cited in note 52).
61. Thea Kalebic, Clear, The Third World Population Is The Most Vulnerable, Letter to the Edi-
tor, 279 Science 1431, 1431 (Mar 6, 1998).
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hosted the trial. In this way, the benefits of the research will be assured to the
community that bears the burden of the research.62
D. CONFLICT BETWEEN THE PRINCIPLES OF
AUTONOMY AND JUSTICE
The most significant challenge for HIV vaccine testing is the conflict between
the requirements of autonomy and the requirements of distributive justice. This
problem arises only in the context of testing treatments for preventable diseases
such as AIDS. A subject who adequately understands and appreciates the risks of
HIV infection will be more likely to use adequate safeguards or abstain from
engaging in high risk activity. This is demonstrated by the falling HIV infection
rates in Uganda which have resulted from "open and concerted" education ef-
forts.63 As autonomous agents, such subjects are ideal for vaccine trials. How-
ever, subjects who use adequate safeguards and abstain from high risk activity
will probably never need a vaccine. Since such subjects will never benefit from
the research, it is unjust to impose the burdens of vaccine testing on them.
The problem extends beyond ethical concerns of justice. Subjects who com-
pletely avoid risk of infection are scientifically useless for evaluating the efficacy
of a vaccine. When vaccine testing is done on animals, researchers intentionally
challenge vaccinated animals with the live virus to test the protective capability
of the vaccine. If the vaccine has worked, the animal will remain healthy. If the
vaccine has failed, the animal will get the disease. In human vaccine testing, of
course, vaccinated subjects cannot be intentionally challenged with live virulent
HIV. Instead, studies must compare the number of HIV infected individuals in
placebo and vaccinated groups. The lower the incidence of HIV infection in the
overall population of subjects, the larger the enrollment needs to be in order to
yield statistically significant results regarding the efficacy of the vaccine. In a
completely autonomous population that safeguarded itself against infection, it
would be impossible to evaluate vaccine efficacy. However, no population is so
completely rational. Each potential pool of subjects is exposed to HIV with
some frequency. Analyzing the suitability of a subject pool for vaccine trials re-
quires an evaluation of the relative weight of autonomy and justice concerns in
that population.
62. Although there is wide agreement that the research sponsor should provide the benefits
of the research to the communities that participated in the trial, there is a great deal of contro-
versy about the details of how and to what extent this should be done. For example, how
broadly is community defined? Should products be provided free, or at reduced cost? For how
long? These questions are beyond the scope of this paper.
63. UNAIDS and WHO, "Regional Round Up," Report on the Global HIV/AIDS Epidemic,
(cited in note 1).
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III. PROPOSALS FOR SUBJECT SELECTION
By applying the principles of autonomy, beneficence, and justice, the follow-
ing section will show that ethical imperatives can be satisfied for all phases of
vaccine testing. Three populations have been proposed for testing a live-
attenuated HIV vaccine. The International Association of Physicians in AIDS
Care (JAPAC), in conjunction with Dr. R. Desrosiers and Therion Biologics
Corp., have proposed phase I safety testing on physicians and health care work-
ers.64 Dr. J Sullivan has proposed using terminal cancer patients with untreatable
solid tumors for phase I trials.65 Finally, citizens of developing countries, notably
Thailand 66 and Uganda,67 are currently hosting phase Ill trials of subunit vac-
cines, and are likely candidates for testing a live-attenuated vaccine.
A. PHYsICIANS
Physicians are ethically the most appropriate pool of subjects for phase I
safety trials of live HI-V vaccines. Physicians already involved in AIDS treatment
are nearly ideal candidates when it comes to satisfying the requirements of the
principle of autonomy. As in any HIV vaccine trial, the potential for great bene-
fit to society merits strong consideration under the principle of beneficence.
However, no interpretation of distributive justice comes out in favor of using
physicians as subjects in the trial, since physicians face a greater risk of HIV in-
fection from the trial than from their normal occupation. The tradeoffs between
autonomy and justice suggest that the participation of physicians be restricted to
phase I testing.
According to the Belmont Report, "there is widespread agreement that the
consent process can be analyzed as containing three elements: information,
comprehension, and voluntariness." 68 While physicians involved in AIDS care
are already well informed about the consequences of infection from a live vac-
cine, the knowledge required to treat patients is distinct from a knowledge of the
science behind the vaccines being proposed. Therefore, physicians will need to
be educated about the nature of the vaccine and the degree of risk associated
with the trial. The unique advantage of physician subjects is their manifest ability
to comprehend the information at a high level. The Belmont Report identifies
64. Shelton, 41 Am Med News (cited in note 3); Proposed Live HITV Vacdne, 12/1/97 AVAB,
1997 WL 9577778 (cited in note 4).
65. Id. Many of the arguments that apply to terminal cancer patients also apply to death row
inmates: since they will die in any case, vaccine testing will not really harm them. However, the
additional risk of coercion in the prison setting makes death row inmates particularly unsuitable
candidates.
66. Baiter, 279 Science at 650 (cited in note 22).
67. Barenzi and Wendo, AIDS Vacine Trials to Start, Africa News Service (Mar 5, 1998)
(cited in note 5).
68. The Belmont Report at 5 (cited in note 25).
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"intelligence, rationality, maturity and language"69 as requisite traits for compre-
hension. Not only are these traits job requirements for physicians, but their
strengths in these areas are directly related to their ability to comprehend the
type of information likely to be presented in informed consent documents for an
HIV vaccine trial. Physicians are as near to ideal participants as is possible as far
as information and comprehension are concerned.
Voluntariness, however, is as difficult an issue for physicians as it is for any
other subject pool. The IAPAC, which is calling for volunteers to participate in
the trials, has characterized participation in vaccine trials as a "moral imperative,"
and emphasized that "[t]here are millions of lives at stake." 70 These are strong
words that have particularly great resonance for physicians in general, who are
sworn to protect lives, and for AIDS physicians in particular, who are acutely
sensitive to the social and moral problems associated with HIV. Dr. Mike Youle,
director of HIV clinical research at the Royal Free hospital in London and a trial
volunteer, says "[o]f course I am putting myself at risk and so will any other vol-
unteers, but I think there is a certain moral imperative to do this."71 The Bel-
mont Report warns that "[u]njustifiable pressures usually occur when persons in
positions of authority or commanding influence ... urge a course of action for a
subject."7 2 Among individuals in a peer group of physicians, no one possesses
authority to a degree that should trigger concern. However, a "commanding
influence" is exerted when a professional organization as a whole takes a stance.
It is important to distinguish the laudable altruism of physician-subjects from
decisions that may have been induced by "undue influence." It would be possi-
ble to ameliorate this problem by disqualifying members of IAPAC from partici-
pation in trials sponsored by their organization. While other physicians might
initially be less familiar with the risks of the trial, they are equally competent to
comprehend and accept those risks. However, such a rule would exclude some
of the best informed subjects, many of whom would probably volunteer even in
the absence of external influences. A less drastic solution might be to appoint a
consent auditor for the trial in order to provide some extra protection for the
participants. In any case, careful subject selection from among the physician
volunteers could allay concerns about voluntariness. Once these concerns have
been addressed, trials on physician subjects will meet the requirements of the
ethical principle of autonomy.
To determine whether a trial satisfies the ethical principle of beneficence, the
risks of the trial must be weighed against the benefits. In the case of a live-
attenuated vaccine, there is a risk that the vaccine will actually cause AIDS or
cancer over the lifetime of the subject. According to the Belmont Report, the
69. Id at 12.
70. Shelton, 41 Am Med News, quoting Charles Farthing, M.D., chair of IAPAC's live-
attenuated vaccine subcommittee and medical director of the AIDS Healthcare Foundation in
Los Angeles (cited in note 3).
71. Ungoed-Thomas, Doctor to Test HIV Vaccine on Himself, Sunday Times- London (cited in
note 3).
72. The Belmont Report at 14 (cited in note 25).
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"manifest voluntariness" of the subject is an acceptable counterweight to high
levels of risk under the principle of beneficence. 73 The Nuremberg Code even
allows for the possibility of experiments that carry a risk of "death or disabling
injury ... in those experiments where the experimental physicians also serve as
subjects." 74 This is not an abstract proposition in the history of vaccine research.
Waldemar Haffkine was his own first subject when he developed a killed vaccine
for the plague in India in 189757 In 1987, Dr. Daniel Zagury injected himself
with the first HIV vaccine tested on humans.76 Thus, the strength of the in-
formed consent that physicians can provide mitigates some of the risks involved
in being a subject in an HIV vaccine trial.
Under the principle of beneficence, we are instructed to look not only at the
risks and benefits to the individual patient, but also to "the importance of the
knowledge that may reasonably be expected to result."7 In the case of physician-
subjects, there is almost no possibility of direct benefit to the individual subjects.
Therefore, the analysis for this patient population depends on whether the bene-
fit to society justifies the risk to individual subjects. In the 1994 edition of Vac-
cines Susan and Stanley Plotkin argue that
[t]he impact of vaccination on the health of the world's peoples is hard to exag-
gerate. With the exception of safe water, no other modality, not even antibiot-
ics, has had such a major effect of mortality reduction and population growth. 8
In a utilitarian calculation, the potential benefit of preventing over two million
deaths a year carries heavy weight This benefit, in combination with the "mani-
fest voluntariness" of the subjects, outweighs the considerable risk associated
with phase I trials of live-attenuated vaccines. Therefore, the risk/benefit calcula-
tion comes out in favor of using physicians as subjects.
It is the third Belmont principle, justice, that presents a particular challenge to
the use of physicians as vaccine trial subjects. The principle of justice demands
that "research should not unduly involve persons from groups unlikely to be
among the beneficiaries of subsequent applications of the research."79 Aside
from their exposure at work, there is no reason to think that physicians are at
any higher risk of acquiring HIV than members of comparable demographic
groups. In the entire history of HIV in the U.S., only 114 health care workers
have-ever acquired HIV through occupational transmission. This is because the
73. Id at 17.
74. The Nuremberg Code, in Annas and Grodin, The Nazi Doctors at 2 (cited in note 34).
75. Plotkin and Plotkin, A Short History of Vaccination, 1, 4 (cited in note 52).
76. Philip J. Hilts, French Doctor Testing AIDS Vaccine on Self, Wash Post Al (Mar 19, 1987).
77. 56 Fed Reg 28003, 28015-6 (111(a)(2)) (cited in note 29).
78. Plotkin and Plotkin, A Short History of Vaccination at 1 (cited in note 52).
79. The Belmont Reoort at 10 (cited in note 25).
80. Fifty-two of these cases have been documented and confirmed. The remaining 62 have
not been proven, but "[tlhese health care workers have been investigated and are without identi-
fiable behavioral or transfusion risks; each reported percutaneous or mucocutaneous occupa-
tional exposures to blood or body fluids, or laboratory solutions containing HIV." 9 HIV/AIDS
Surveillance Report at 15 (table 11, 3) (cited in note 7).
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use of universal precautions for sterility in medicine has effectively prevented
infection of health care workers on the job. Therefore, physicians are unlikely to
benefit directly from the development of a vaccine.
The problem of justice is not insurmountable. The Belmont Report requires
only that "research should not unduly involve persons from groups unlikely to
be among the beneficiaries of subsequent applications of the research (emphasis
added)."'81 The inclusion of the modifier "unduly" suggests that some mismatch
between benefits and burdens is acceptable when the benefits of the research are
substantial. The main focus of the Belmont Report's discussion of justice is the
protection of vulnerable populations such as prisoners and the poor, who have
historically been exploited as research subjects. Certainly, the principle of justice
was not elaborated in the Belmont Report for the purpose of protecting physi-
cians. Furthermore, while the Belmont Report assigns no priority to its three
principles, one could argue that the acceptability of physicians with respect to the
principles of autonomy and beneficence outweigh their inappropriateness with
respect to the principle of justice. By this analysis, physicians are excellent candi-
dates for phase I clinical trials of vaccine safety and immunogenicity. However,
because of their low baseline rate of infection, physicians are not scientifically
useful for phase II or phase III trials, which require rates of infection high
enough to test the efficacy of the vaccine in a reasonably sized cohort.
B. TERMINAL CANCER PATIENTS
Terminal cancer patients are not ethically acceptable subjects for HIV vaccine
trials. Traditionally, terminal patients have been regarded as poor subjects from
the standpoint of autonomy. Patients facing death may be easy targets for coer-
cion and may be unduly influenced to cling to improbable hope. However, these
undue influence concerns are absent in the case of HIV vaccine trials. Neverthe-
less, cancer patients are unacceptable subjects from the standpoint of benefi-
cence because of the possibility of hastening their deaths. Furthermore, by par-
ticipating in HIV vaccine trials these patients will be unsuitable subjects for ex-
perimental cancer protocols. Finally, the principle of justice argues that terminal
cancer patients should not be used in HIV vaccine trials because they will not
benefit from the research.
Cancer patients raise two concerns about the ability of research subjects to
make autonomous decisions. First, the absolute dependence of the patient on his
physician makes almost any suggestion by the physician coercive. As one com-
mentator explains:
When "informed consent" is obtained, it is not the student, the destitute bum,
or the prisoner to whom, by virtue of his condition, the thumb screws of coer-
81. The Belmont Report at 10 (cited in note 25).
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don are most relentlessly applied; it is the most used and useful of all experi-
mental subjects, the patient with disease. 2
Second, there is a degree of desperation that (legitimately) accompanies a ter-
minal illness and that may interfere with the ability of the patient to comprehend
his situation and the possible consequences of a proposed trial. However, when
asking a terminal patient to participate in research for another illness, it is likely
that both of these concerns can be minimized. It is unlikely that a cancer pa-
tent's oncologist will also be an investigator for a clinical trial of an HIV vaccine.
Therefore, the oncologist could legitimately reassure her patient that his care
would not be affected by his decision. Furthermore, it is dear even to the most
desperate cancer patient that no clinical benefit will come to him from participa-
tion in an HIV vaccine trial Therefore, the only consideration which could mo-
tivate a terminal cancer patient to participate in such a trial would be altruism.
This is a legitimate motive for any person of sound mind, and is in some ways
similar to the risk we allow otherwise healthy kidney donors to assume for the
benefit of others.8 3 Therefore, terminal cancer patients are acceptable subjects
for HIV vaccine trials from the standpoint of autonomy.
The most common argument in favor of using terminal patients for clinical
trials of any sort is that they have "nothing to lose." If this were true, HIV vac-
cine trials for terminal cancer patients would fall under the "minimal risk" ex-
emption of the DHHS regulations.8 The Supreme Court rejected a similar ar-
gument in 1979 in United States v Rutherford,85 based on the fact that "With dis-
eases such as cancer it is often impossible to identify a patient as terminally ill
except in retrospect"8 6 A patient who recovered from their cancer because of a
new treatment or an unexplained remission would face a small risk of a second
terminal illness from the HIV vaccine.8 7 Even in the case of a correctly diag-
nosed terminal patient, there is a small risk that damage to their immune system
caused by the vaccine would hasten their death. Most importantly, enrollment in
a clinical trial for an HIV vaccine causes harm to terminal cancer patients by
disqualifying them from participation in clinical trials of experimental cancer
therapies. The only aspect of the risk/benefit analysis which weighs in favor of
82. George J. Annas, Faith (Hea#ng), Hope and Cbadry at the FDA: The Po#tis of AIDS Drug
Trials, 34 Viii L Rev 771, 777 (1989).
83. Of course, the benefit in the case of organ donation is direct and tangible compared to
the more abstract benefit gained from some unquantifiable progress in the fight against AIDS.
84. 56 Fed Reg 28003, 28013 (§102(1)) (cited in note 29).
85. 442 US 544, 551 (1979). Based on the FDA guidelines in force at the time, the Supreme
Court held that there was no exception to the safety and efficacy requirements even for termi-
nally ill cancer patients seeking access to the experimental drug Laetdle.
86. Rutberford, 442 US at 556.
87. The pace at which new treatments are developed means that the definition of "terminal"
is fluid, and provides a poor basis for subject selection. For example, Dr. Sullivan proposed
using "terminal cancer patients with untreatable solid tumors" in 1997. Proposed Live HI' Tac-
dne Trials, 12/1/97 AVAB, 1997 WL 9577778 (cited in note 4). This is precisely the type of
patient who would have been considered terminal at the time of Dr. Sullivan's proposal, but
would now be considered an excellent candidate for trials of new anti-angiogenic compounds.
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using terminal cancer patients is that they are already subject to medical interven-
tions. Therefore, travel to the hospital, injections, and taking of blood samples,
which would be substantial burdens for healthy patients, would not significantly
change a terminal cancer patient's normal routine.88 These risks are not balanced
by any benefits, because there is no possibility that the cancer patients will expe-
rience any direct benefit from the HIV vaccine.
Finally, cancer patients are unsuitable subjects for an HIV vaccine trial accord-
ing to the principle of distributive justice. Since they are in a hospital environ-
ment, terminal cancer patients are at very low risk for becoming infected with
HIV. Therefore, they are poor vaccine trial subjects under the principle of dis-
tributive justice. Also, as low risk subjects, terminal cancer patients are scientifi-
cally inappropriate for phase II or phase III clinical trials.
For phase I trials, terminal cancer patients have a slight advantage over physi-
cians under the principle of autonomy because they are largely free from undue
influence or coercion in trials not related to their illness. However, their capacity
to understand the informed consent material will likely be substantially less than
that of physicians and they likely cannot be allowed sufficient time for reflection.
Furthermore, the participation of terminal cancer patients in HIV vaccine trials
risks hastening their death, and precludes their participation in potentially bene-
ficial cancer therapy trials while providing no direct benefit to them whatsoever.
Finally, because they are at low risk of acquiring HIV, the principle of justice also
dictates that terminal cancer patients are inappropriate subjects for any phase of
HIV vaccine testing.
C. CITIZENS OF DEVELOPING COUNTRIES
The population ethically and scientifically best suited for larger scale trials is a
population of subjects from developing countries with a high incidence of HIV
infection. Current guidelines for international research require that the principles
of respect for persons, beneficence, and justice guide experimentation in devel-
oping countries. 89 The controversy surrounding trials in developing countries is
fueled by desperate calls to relax these ethical guidelines in response to the mag-
nitude of the AIDS pandemic.90 Opponents of these trials fear ethical relativ-
ism,91 and claim that "[tihe refusal or disinclination of populations in developed
countries to enroll in studies should serve notice that they are equally unaccept-
88. "Risks to subjects are minimized ... by using procedures already being performed on the
subjects for diagnostic or treatment purposes." 56 Fed Reg 28003, 28015 (§11(a)(1)(ii)) (cited in
note 29).
89. Bloom, The Higbest Attainable Standard, 279 Science at 186 (cited in note 5), citing the
Council for International Organizations of Medical Sciences (CIOMS) and the World Health
Organization (WHO) International Ethical Guidelines for Biomedical Research Involving Human Subjects,
(Geneva, 1982; revised in 1993); and the World Medical Association, Declaration of Helsinki,
(1964; revised in 1974, 1983, 1989, 1996).
90. Bloom, 279 Science at 186 (cited in note 5); Edward Mbidde, Bioethics and Local Ciratm-
stances, 279 Science 155, 155 (Jan 9, 1998).
91. Kalebic, Letter to the Editor, 279 Science at 1431 (cited in note 61).
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able in the developing world."9 However, both of these opinions ignore the
possibility that different outcomes in different countries can still be legitimate
under the Belmont Report's normative prnciplesY3 First of all, citizens of devel-
oping countries have demonstrated their autonomy by their capacity to under-
stand and act on information about HIV. Second, risk/benefit calculations that
take local circumstances into account can determine whether a trial in a particu-
lar developing country satisfies the principle of beneficence. Finally, the principle
of distributive justice argues strongly in favor of conducting vaccine trials in de-
veloping countries with a high incidence of HIV, since citizens of those coun-
tries stand to benefit most from the knowledge and products that result. Where
adequate medical and ethical safeguards are taken, developing countries provide
the best testing grounds for phase HI determinations of vaccine efficacy.
One of the common objections to clinical trials performed on citizens of de-
veloping countries is that such populations will be unable to meet the require-
ments of the principle of autonomy. Proponents of this argument point out that
citizens of developing countries are more vulnerable than citizens in developed
countries, 94 and that tribal interests take priority over individual rights in most
African systems of customary law.95 These arguments are specious and paternal-
istic. The success of public health campaigns in reducing the number of new
FIV infections in Uganda indicates that developing countries are capable of
disseminating relevant information, and that their citizens are capable of under-
standing, processing, and acting on such information. Furthenmore, community-
mindedness is a major motivation for volunteers in vaccine trials throughout the
developed world,96 and does not per se indicate a deficiency in information, ca-
pacity, or voluntariness.
Beneficence and non-maleficence arguments provide the strongest case for
phase I trials in developing countries. A subject that is at high risk of becoming
infected with HIV will receive substantial beneficial effects even from a vaccine
that is only partially protective. The beneficial effects of a treatment can be con-
ceived of as being composed of two variables: the magnitude of the benefit, and
the probability of the benefit The probability of the benefit depends on the
probability that the vaccine will be successful and on the probability that a given
subject will be exposed to HIV.97 Taking magnitude and probability into account
yields a value that reflects the expected benefit of the treatment to an individual
92. M. Dickens, Research Ethics and HIV/AIDS, 16 MEDLAW 187, 195 (1996).
93. "While ethical principles ... remain universal, it is recognized that biological circum-
stances can validly affect the decision process." OTA, Adverse Reactions to HIV Vaccines at 58
(cited in note 20).
94. Kalebic, 279 Science at 1431 (cited in note 61).
95. Pen H. Alkas, J.D. and Wayne X. Shandera, M.D., HV and AIDS in Africa: African Pol-
des in Response to AIDS in Relation to Various National Legal Traditions, 17 J Leg Med 527, 531
(1996).
96. AVEU, In Their Own Words - The Volunteers Spieak (cited in note 46).
97. Of course, the subject does not benefit from the vaccine if he is never exposed to HIV
and the vaccine never has a chance to protect him.
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subject.98 This approach to evaluating the beneficial effects of a treatment mir-
rors the risk calculation component of the beneficence analysis. As the Belmont
Report points out, the term risk commonly refers "both to the chance (probabil-
ity) of experiencing a harm and to the severity (magnitude) of the envisioned
harm."99 Furthermore, an expected benefit approach to analyzing the beneficial
effects of a treatment is justified by the Belmont Report's admonition that "the
idea of systematic, nonarbitrary analysis of risks and benefits should be emulated
insofar as possible."1' °
In the case of a drug that is given to a person who has been diagnosed with a
particular illness, the probability of exposure to the illness is one; that is, the pa-
tient definitely has the illness and will definitely benefit from any protective ef-
fect of the drug. Therefore, the beneficial effect of the drug can be described
simply by quantifying the probability of success of the drug. In the case of a vac-
cine, the beneficial effect can only be fully characterized if both the probability
of success and the probability of exposure are taken into account. Thus, in
evaluating the beneficial effect of a vaccine on a particular subject, we must take
into account both the effectiveness of the vaccine and the likelihood that the
subject will be exposed to the pathogen. Therefore, the more prevalent the dis-
ease, the greater the beneficial effects of the vaccine.0 1 For example, a subject
who bears a 40 percent risk of contracting HIV by virtue of belonging to a high
risk population will receive a 28 percent beneficial effect from a vaccine that is
70 percent effective in protecting people from contracting HIV.10 2 This means
that if a subject is vaccinated, he will have a 28 percent chance of being exposed
to HIV but not contracting it. Even if the vaccine carries a 1 percent risk of giv-
ing the subject HIV,103 the total chance of the subject getting HIV is reduced
98. This conception of beneficial effect can be described by the following equation:
beneficial effect = expected benefit
= (magnitude of benefit) x (prob. of benefit)
= (magnitude of benefit) x (prob. of success) x (prob. of exposure)
99. Belmont Report at 15 (cited in note 25). The risk calculation can be depicted as follows:
risk = expected harm = (magnitude of harm) x (prob. of harm)
100. Id at 16.
101. This explains, for example, why Thai authorities have authorized phase III trials of sub-
unit vaccines that showed no preliminary evidence of effectiveness in phase I and II trials in the
U.S. The risk of the subunit vaccines has been proven to be minimal in phases I and II. Whereas
a protective effect too small to be detected in phase II provides small incremental benefit to
U.S. populations, the incidence among some communities in Thailand is so high that even a tiny
protective effect translates into significant numbers of lives saved.
102. This result is reached by plugging the risk of being exposed to HIV and the effectiveness
of the vaccine into the equation set out in footnote 97 as follows:
beneficial effect = 70% x 40% = 28%
Because of the availability of epidemiological data, this type of calculation will often be fairly
easy to carry out. Note that the magnitude of the harm of contracting HIV and the magnitude
of the benefit of avoiding HIV are the same. Because these magnitudes appear on both sides of
the risk/benefit analysis, they cancel each other out and so the magnitude variable can be ig-
nored.
103. This risk would be unacceptably high in the U.S., since the overall prevalence of HIV in
the U.S. is approximately 0.1 percent. A one percent risk of getting HIV from a vaccine would
be ten times higher than the risk of getting HIV with no vaccine at all.
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from 40 percent to 13 percent.10 4 Because the beneficial effects of a trial increase
with the incidence of HIV in the population, high-risk populations in developing
countries will often be ideal for HIV vaccine trials.
There is a problem with this analysis. The beneficial effect of a vaccine to sub-
jects in developing countries depends on the subjects being at high risk for HIV.
However, ethical considerations require that we take every possible measure in
parallel with vaccination to ensure that subjects take action to avoid infection. If
these measures, such as public education, really matched prevention efforts in
developed countries, they should be able to reduce infection rates in the devel-
oping country to the rates observed in the sponsoring nation. However, there is
a point at which continued education by the sponsor will reduce the number of
new HIV cases in the subject population less than the reduction expected from
the vaccine. At this point, the incidence of HIV infection in the developing
country might still be higher than in the sponsoring country, but the sponsors
can be said to have adequately met their ethical obligation to educate the sub-
jects.
Trials of HIV vaccines in developing countries are also strongly supported by
arguments of distributive justice. Trial subjects come from high risk populations,
so it is appropriate to ask them to bear the burden of participating in research
trials. Their participation, however, imposes an obligation on the part of the
sponsor "to make vaccine available to the community in which the trial was con-
ducted ... for free or at cost" at the conclusion of the tdal. 05 Furthermore, there
is an ethical and scientific imperative to perform vaccine trials with virus sub-
types appropriate to those prevalent in the subject population.10 6 These proce-
dures ensure that, having borne the burden of participation, the host community
shares in the benefits that result.
Even according to the rigorous standards of the Belmont Report, phase III
vaccine efficacy trials in developing countries are ethical. The 1993 CIOMS
guidelines advocate "applying ethical standards in local circumstances." In the
case of using subjects from developing countries, such application reveals a very
powerful beneficence argument that is unique to populations with a high inci-
dence of HIV. Furthermore, the justice of performing trials on a population that
stands to benefit greatly from the resulting vaccine is attractive. Finally, concerns
about the vulnerability of citizens of developing countries are paternalistic, and
ignore the existence of sophisticated mechanisms for scientific and ethical review
which are in place in the countries participating in vaccine efficacy trialsj 07 The
same characteristics that make developing countries appropriate hosts for phase
III trials also make them appropriate hosts for phase II trials.108
104. Thirteen percent is the chance that the vaccine failed to protect against environmental
exposure (40% - 28% = 12%) plus the chance that the vaccine gave the subject HIV (1%).
105. OTA, Adverse Reactions to HIV Vaccines at 75-76 (cited in note 20).
106. Id at 73 (cited in note 20).
107. Mbidde, Bioethics and Local Circumstances, 279 Science at 155 (cited in note 90).
108. Bloom, Bioethics and Local Circumstances, 279 Science at 188 (cited in note 5).
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IV. CONCLUSION
This paper considered the appropriateness of three subject pools for testing
live-attenuated HIV vaccines. Each population was evaluated for its suitability
according to the three Belmont Report principles: autonomy, beneficence, and
justice. This analysis revealed that physicians are the most suitable subject popu-
lation for phase I trials because of their great capacity to make autonomous deci-
sions. Terminal cancer patients are unacceptable for any phase of HIV vaccine
testing because their participation would preclude their participation in cancer
treatment trials; therefore, trials involving terminal cancer patients do not meet
the requirements of beneficence. Finally, citizens of developing countries are the
most appropriate populations for phase II and phase III trials because the ex-
pected benefit of such trials will be relatively high due to the prevalence of HIV
in these populations.
